Untersuchungen zum Agonismus hexavalenter und dodekavalenter anti-TNFR-Antikörper
- Alternative title
-
Studies on the agonism of hexavalent and dodecavalent anti-TNFR-antibodies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Deutsch
- Notes
-
Würzburg, Universität Würzburg, Dissertation, 2024
- Keyword
-
Immuntherapie
Tumor-Nekrose-Faktor
Immuntherapie
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2024
- Creator
-
Haile, Bianca
- Contributor
-
Wajant, Harald
- DOI
-
10.25972/OPUS-38814
- URN
-
urn:nbn:de:bvb:20-opus-388140
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Haile, Bianca
- Wajant, Harald
- Universität Würzburg
Time of origin
- 2024
Other Objects (12)
Molecular mode of action of TRAIL receptor agonists—common principles and their translational exploitation
Herstellung und Charakterisierung von anti-CD40- und anti-41BB-Fusionsproteinen mit PDL1-abhängiger agonistischer Aktivität
Development of self-adjusting cytokine neutralizer cells as a closed-loop delivery system of anti-inflammatory biologicals
The importance of antibody isotype and idiotype in FcγR-dependent agonism induced by anti-CD40 antibodies
Entwicklung und Charakterisierung von Gaussia princeps Luziferase-Antikörper-Fusionsproteinen
Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
Enhancement of Toll-like receptor3 (TLR3)-induced death signaling by TNF-like weak inducer of apoptosis (TWEAK)
CD40-restringierte Aktivierung der TRAIL-Todesrezeptoren durch bifunktionelle rekombinante Proteine
Development of Modified polylysine based antibody conjugated nanoparticles with tumor-restricted, FcγR-independent stimulatory activity by targeting Fn14
Development of CD40-targeted bifunctional scFv-TRAIL fusion proteins that induce TRAILR1- and TRAILR2-specifc cell death and dendritic cells activation
CD70-abhängige und spezifische Aktivierung von TRAILR1 oder TRAILR2 durch scFv:CD70-TRAIL-Mutanten
Entwicklung CD40/DC-stimulierender rekombinanter Proteine mit Tumorantigen-restringierter Aktivität
Molecular mode of action of TRAIL receptor agonists—common principles and their translational exploitation
Herstellung und Charakterisierung von anti-CD40- und anti-41BB-Fusionsproteinen mit PDL1-abhängiger agonistischer Aktivität
Development of self-adjusting cytokine neutralizer cells as a closed-loop delivery system of anti-inflammatory biologicals
The importance of antibody isotype and idiotype in FcγR-dependent agonism induced by anti-CD40 antibodies
Entwicklung und Charakterisierung von Gaussia princeps Luziferase-Antikörper-Fusionsproteinen
Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
Enhancement of Toll-like receptor3 (TLR3)-induced death signaling by TNF-like weak inducer of apoptosis (TWEAK)
CD40-restringierte Aktivierung der TRAIL-Todesrezeptoren durch bifunktionelle rekombinante Proteine
Development of Modified polylysine based antibody conjugated nanoparticles with tumor-restricted, FcγR-independent stimulatory activity by targeting Fn14
Development of CD40-targeted bifunctional scFv-TRAIL fusion proteins that induce TRAILR1- and TRAILR2-specifc cell death and dendritic cells activation
CD70-abhängige und spezifische Aktivierung von TRAILR1 oder TRAILR2 durch scFv:CD70-TRAIL-Mutanten
Entwicklung CD40/DC-stimulierender rekombinanter Proteine mit Tumorantigen-restringierter Aktivität
Molecular mode of action of TRAIL receptor agonists—common principles and their translational exploitation
Herstellung und Charakterisierung von anti-CD40- und anti-41BB-Fusionsproteinen mit PDL1-abhängiger agonistischer Aktivität
Development of self-adjusting cytokine neutralizer cells as a closed-loop delivery system of anti-inflammatory biologicals
The importance of antibody isotype and idiotype in FcγR-dependent agonism induced by anti-CD40 antibodies
Entwicklung und Charakterisierung von Gaussia princeps Luziferase-Antikörper-Fusionsproteinen
Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
Enhancement of Toll-like receptor3 (TLR3)-induced death signaling by TNF-like weak inducer of apoptosis (TWEAK)
CD40-restringierte Aktivierung der TRAIL-Todesrezeptoren durch bifunktionelle rekombinante Proteine
Development of Modified polylysine based antibody conjugated nanoparticles with tumor-restricted, FcγR-independent stimulatory activity by targeting Fn14
Development of CD40-targeted bifunctional scFv-TRAIL fusion proteins that induce TRAILR1- and TRAILR2-specifc cell death and dendritic cells activation
CD70-abhängige und spezifische Aktivierung von TRAILR1 oder TRAILR2 durch scFv:CD70-TRAIL-Mutanten